

Haematologica
HAEMATOL/2018/191999
Version 3

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau,
Lian Xu, Guang Yang, Zachary R. Hunter, Ranjana Advani, Lia
Palomba, and Steven P. Treon

Disclosures: JJC has received honoraria and/or research funds from Abbvie, Beigene, Gilead, Janssen, Millennium and Pharmacyclics. LP has received honoraria from Pharmacyclics, Merck and Celgene. SPT has received research funding and/or consulting fees from Pharmacyclics Inc. and Janssen Pharmaceuticals.

Contributions: JJC and JNG designed the study and performed the analysis. JNG gathered the data. JJC drafted the manuscript. LX, GY and ZRH performed molecular testing in patients' samples. All the authors took care of the patients, and critically reviewed and approved the final manuscript.